Sugi Predict

Sugi Predict / Compounds / SCHEMBL6042212

SCHEMBL6042212

SCHEMBL6042212

O=C(O)N1CCC(c2ccc(F)cc2)C(OCc2cc(OCc3ccncc3)c3ccccc3c2)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 1/20 0.39
▸ F10 P00742 4/20 0.38
▸ GRM5 P41594 1/20 0.37
▸ F2 P00734 1/20 0.37
▸ ELANE P08246 1/20 0.37
▸ PTGER1 P34995 2/20 0.36
▸ KDM2B Q8NHM5 1/20 0.36
▸ REN P00797 1/20 0.36
▸ GRM4 Q14833 1/20 0.35
▸ LRRK2 Q5S007 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ HPGD P15428 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ RORC P51449 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ CYP11B1 P15538 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6044005 0.94 KDM2B (0.40) PTGER1KDM2BRENMAPTHPGD
SCHEMBL6041704 0.91 HTT (0.42) MGLLRENGRM4LRRK2MAPT
SCHEMBL6041832 0.91 REN (0.39) F10PTGER1RENMAPTHPGD
SCHEMBL6041290 0.89 REN (0.39) KDM2BRENMAPTHPGDNPC1
SCHEMBL6042261 0.89 CCR3 (0.37) PTGER1KDM2BRENMAPTHPGD
SCHEMBL6042512 0.88 REN (0.42) RENLMNA
SCHEMBL6042864 0.87 REN (0.45) PTGER1RENNPC1RAB9A
SCHEMBL6043330 0.87 KDM2B (0.36) KDM2BRENMAPTHPGDNPC1
SCHEMBL6042154 0.87 REN (0.39) PTGER1RENMAPTRAB9ASMN1; SMN2
SCHEMBL6042134 0.87 REN (0.39) PTGER1RENLRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060079533-A1 Methods of treating alzheimer's disease NIEMAN JAMES A 2006-04-13 — — US disclosed
WO-2002076440-A2 METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES ELAN PHARMACEUTICALS, INC. (US) 2002-10-03 — — WO disclosed
US-6150526-A Piperidine derivative having renin inhibiting activity HOFFMANN-LA ROCHE INC. (US) 2000-11-21 — — US disclosed
US-6051712-A PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS HOFFMANN-LA ROCHE INC. (US) 2000-04-18 — — US disclosed
EP-0863875-A1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY F. HOFFMANN-LA ROCHE AG (CH) 1998-09-16 — — EP disclosed
WO-1997009311-A1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY F. HOFFMANN-LA ROCHE AG (CH) 1997-03-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079533-A1 Methods of treating alzheimer's disease BACE1, PSEN1, PSEN2 MGLL 1480/4885F10 1325/4885GRM5 768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.